Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
21.40
+0.10 (0.47%)
Apr 24, 2025, 2:05 PM CET
17.91%
Market Cap 858.17M
Revenue (ttm) 77.65M
Net Income (ttm) 45.29M
Shares Out 40.29M
EPS (ttm) n/a
PE Ratio 18.95
Forward PE 9.77
Dividend n/a
Ex-Dividend Date n/a
Volume 1,676
Average Volume 12,397
Open 21.30
Previous Close 21.30
Day's Range 21.20 - 21.50
52-Week Range 16.50 - 21.90
Beta 0.11
RSI 67.32
Earnings Date Mar 27, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 165
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.